## A list of all abbreviations and terms appearing in this issue of *Therapy*.

| AcD<br>ADRD | Accessory duct Alzheimer's disease and | EPITHET     | Echoplanar Imaging<br>Thrombolytic Evaluation Trial | OIH<br>OINV | Opioid-induced hyperalgesia Opioid-induced nausea and  |
|-------------|--|-------------|---|-------------|--|
| ADIO        | related disorders                      | FAST        | Face Arm Speech Test                                | Ollav       | vomiting   |
| AF          | Atrial fibrillation                    | FBT         | Fentanyl buccal tablet                              | OP          | Opioid peptide   |
| AFL         | Atrial flutter                         | FOCUS       | Functional Outcomes in                              | OR          | Odds ratio   |
| AGS         | American Geriatric Society             | . 0 003     | Cardiovascular Patients                             | OROS®       | Osmotic controlled-release oral                        |
| AMS         | Addiction medicine specialist          |             | Undergoing Surgical                                 | Onos        | delivery system  |
|             | Acute Physiology and Chronic           |             | Hip Fracture Repair                                 | ORT         | Opioid Risk Tool                                       |
|             | Health Score                           | GDTA        | Goal-directed therapy                               | OTT         | Onset to treatment time                                |
| APM         | Association for Palliative             |             | agreement   | OW          | Opioid withdrawal                                      |
|             | Medicine of Great Britain              | GI          | Gastro-intestinal                                   | PADT        | Pain Assessment and                                    |
|             | and Ireland                            | HAS         | Hepatic artery stenosis                             |             | Documentation Tool                                     |
| ASPECTS     | Alberta Stroke Programme Early         | HAT         | Hepatic arterial thrombosis                         | PAO         | Peripheral acting opioid                               |
|             | CT Score                               | HBOC        | Hemoglobin oxygen-based                             | PCP         | Primary care physician                                 |
| b.i.d.      | Twice a day                            |             | carrier   | PD          | Percutaneous drainage                                  |
| BART        | Blood Conservation Using               | HBsAg       | Hepatitis B surface antigen                         | PELD        | Pediatric End-Stage                                    |
|             | Antifibrinolytics in a                 | HTLV        | Human T-cell lymphocyte virus                       |             | Liver Disease score                                    |
|             | Randomized trial                       | HTLV        | Human T-cell lymphotrophic                          | PEOAS       | Peripheral endogenous opioid                           |
| BBB         | Blood–brain barrier                    |             | virus   |             | analgesic system                                       |
| BD          | Balloon dilatation                     | IBS         | Irritable bowel syndrome                            | P-gp        | P-glycoprotein   |
| BL          | Biliary leak                           | IBS-C       | IBS with constipation                               | PINT        | Premature Infants in Need of                           |
| BP          | Blood pressure                         | IBS-D       | IBS with diarrhea                                   |             | Transfusion  |
| BTP         | Breakthrough pain                      | IBS-M       | Mixed IBS   | PMN         | Polymorphonuclear cell                                 |
| BS          | Biliary stenosis                       | INFS        | Intranasal fentanyl spray                           | PMS         | Primary specialist                                     |
| cAMP        | Cyclic adenosine monophosphate         | INOS        | Inducible nitric oxide synthase                     | POPP        | Preopioid prescribing period                           |
| CBD         | Common bile duct                       | IPT         | Interdisciplinary pain team                         | PR          | Prolonged release                                      |
| COT         | Chronic opioid therapy                 | IRES        | Internal ribosome entry site                        | PROACT      | Prolyse in Acute Cerebral                              |
| CRASH       | Clinical Randomisation of an           | IT          | Intrathecal   |             | Thromboembolism Trials                                 |
|             | Antifibrinolytic in                    | IVIg        | Intravenous immunoglobulin                          | q.i.d.      | Four-times a day                                       |
| CDE         | Significant Haemorrhage                | KOR         | κ-opioid receptor                                   | RABD        | Right anterior bile duct                               |
| CRF         | Corticotrophin-releasing factor        | LDLT        | Living-donor liver transplant                       | RBC         | Red blood cell   |
| CyD         | Cystic duct                            | LT          | Liver transplantation                               | RCOT        | Readiness for chronic opioid                           |
| DAINIGO     | p-Ala2, N-Me-Phe4,                     | LTP         | Long-term potentiation                              | DEMC        | therapy  |
| DCLUb       | Gly5-ol-enkephalin                     | M6G         | Morphine-6-glucuronide                              | REMS        | Risk evaluation and mitigation                         |
| DCLHb       | Diaspirin cross-linked hemoglobin      | MCA<br>MELD | Middle cerebral artery                              | RPBD        | strategies   |
| DD          | Duct-to-duct                           | IVIELD      | Model for End-Stage<br>Liver Disease                | RYHJ        | Right posterior bile duct                              |
| DEA         |  | MMT         | Methadone maintenance                               | SISAP       | Roux-en-Y hepaticojejunostomy Screening Instrument for |
| DEA         | Drug Enforcement Administration        | IVIIVII     | treatment   | SISAP       | Substance Abuse Potential                              |
| DEDAS       | Dose Escalation of Desmoteplase        | MOR         | μ-opioid receptor                                   | SLF         | Sublingual fentanyl                                    |
| DLDAS       | for Acute Ischemic Stroke              | MTT         | Mean transit time                                   | SLU         | Saint Louis University                                 |
| DEFLISE     | Diffusion-weighted imaging in          | NADPH       | Reduced form of nicotinamide                        | SNP         | Single nucleotide polymorphism                         |
| DLIOJL      | Evolution For Understanding            | NADIII      | adenine dinucleotide phosphate                      | SOAPP       | Screener and Opioid Assessment                         |
|             | Stroke Etiology                        | NE          | Norepinephrine                                      | 30/411      | for Patients with Pain                                 |
| DH          | Dorsal horn                            | NF          | Nuclear factor                                      | T2DM        | Type 2 diabetes mellitus                               |
| DHEA        | Dehydroepiandrosterone                 | NGF         | Nerve growth factor                                 | TACO        | Transfusion-associated                                 |
| DIAS        | Desmoteplase In Acute Stroke           | NIHSS       | National Institute of Health                        | 17 100      | circulatory overload                                   |
| DIRE        | Diagnosis, Intractability, Risk,       |             | Stroke Scale  | TCD         | Transcranial Doppler ultrasound                        |
|             | Efficacy                               | NINDS       | National Institute of                               | THC         | Tetrahydrocannabinol                                   |
| DO2         | Oxygen delivered                       |             | Neurological Disorders                              | TLR4        | Toll-like receptor 4                                   |
| DOR         | δ-opioid receptor                      |             | and Stroke  | TRALI       | Transfusion-related acute                              |
| DRD2        | Dopamine receptor D2                   | NK-1R       | NK-1 receptor                                       |             | lung injury  |
| DRG         | Dorsal root ganglion                   | NMDA        | N-methyl-p-aspartic acid                            | TRICC       | Transfusion Requirements in                            |
| ECASS       | European Cooperative Acute             | NO          | Nitric oxide  |             | Critical Care  |
|             | Stroke Studies                         | NOSE        | Numerical Opioid Side Effect                        | VTA         | Ventral tegmenal area                                  |
| ECG         | Electrocardiogram                      | OIAE        | Opioid-induced adverse effect                       | VTEU        | Vaccine and treatment                                  |
|             |  |             |   |             | evaluation unit  |
|             |  |             |   |             |  |